Bausch Health (BHC)
(Delayed Data from NYSE)
$5.63 USD
-0.47 (-7.70%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $5.62 -0.01 (-0.18%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth F Momentum B VGM
Price, Consensus and EPS Surprise
BHC 5.63 -0.47(-7.70%)
Will BHC be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for BHC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for BHC
Bausch Health (BHC) Q2 Earnings In Line, Xifaxan Boosts Sales
Bausch (BHC) Reports Q2 Earnings: What Key Metrics Have to Say
BHC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Bausch Health (BHC) Beats Q2 Earnings and Revenue Estimates
Bausch Health (BHC) Earnings Expected to Grow: Should You Buy?
Bausch (BHC) Q1 Earnings and Revenues Miss, Shares Fall
Other News for BHC
Bausch Health Companies (BHC) Gets a Hold from Truist Financial
RBC Capital Remains a Hold on Bausch Health Companies (BHC)
Bausch Health: A Balanced Hold Amid Revenue Growth and Operational Challenges
Piper downgrades Bausch Health to Underweight with solvency 'top of mind'
Bausch Health Companies: Sell Rating Reiterated Amid Spin-Off Uncertainties and Financial Concerns